Company / EPS (Diluted)
BridgeBio Pharma, Inc. EPS (Diluted) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.95
FY2025
5-year range
-$3.95 / -$2.48
FY2021-FY2025
Trend
-21.2%
vs FY2024
Sector context
#163 of 204
Health Care
What the data says
BridgeBio Pharma, Inc.'s eps (diluted) of $-3.95 is lower than 80% of companies in the Health Care sector (FY2025).
Based on SEC 10-K filings.
-3.95 in FY2025.
Remained stable around $-3.95 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 204This company -$3.95 Sector average -$0.98
▼
-303.2% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 21.2% year-over-year.
- Ranks #163 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.95 | -21.2% |
| FY2024 | -$3.26 | +16.4% |
| FY2023 | -$3.90 | -2.6% |
| FY2022 | -$3.80 | -53.2% |
| FY2021 | -$2.48 | -17.0% |
| FY2020 | -$2.12 | -112.0% |
| FY2019 | -$1.00 | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026